Trial · NCT00949091
Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes
NCT00949091, Phase 1, Completed, Takeda
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes. Trials, record NCT00949091. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00949091
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes
- NCT number
- NCT00949091
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 60 participants, actual
- Lead sponsor
- Takeda
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- TAK-875
- First posted
- 2009-07-30
- Last updated
- 2010-06-11
Source ClinicalTrials.gov
Registered outcomes54
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | TAK-875 maximum observed plasma concentration (Cmax) | Day 14 | |
| Primary | TAK-875 time at which Cmax occurred (Tmax) | Day 14 | |
| Primary | TAK-875 area under the plasma concentration-time curve from time 0 to time tau, where tau is the length of a dosing interval AUC(0-tau) | Day 14 | |
| Primary | TAK-875 renal clearance (CLr) | Day 14 | |
| Primary | TAK-875 metabolite (M-I) Cmax | Day 14 | |
| Primary | TAK-875 M-I Tmax | Day 14 | |
| Primary | TAK-875 M-I AUC(0-tau) | Day 14 | |
| Primary | TAK-875 M-I renal clearance CLr | Day 14 | |
| Secondary | TAK-875 Cmax | Day 1 | |
| Secondary | TAK-875 Tmax | Day 1 |
1 to 10 of 54Source ClinicalTrials.gov
See all 54 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00949091
GET https://conductscience.org/api/trials/v1/NCT00949091/registered?page=2